Salubris, recently announced the completion of enrollment in the Phase 3 clinical trial study of S086 in patients with hypertension.
S086 is an angiotensin II receptor- Neprilysin dual inhibitor with targeted indications for hypertension and chronic heart failure (HFrEF). S086 is the second ARNi-type small molecule in the world to enter the clinic trial study. In December 2021, the first patient in this Phase III clinical trial for mild to moderate primary hypertension was enrolled. After eight months, the enrollment was successfully completed.
The clinical trial of S086 tablet has made positive progress. When the product is launched, it will benefit more hypertensive patients and help Salubris maintain high-quality development in the cardiovascular area.
Clinical trial related
This trial is a randomized, double-blind, active drug parallel-controlled, multi-center phase 3 clinical study, of which the PI (principal investigator) is Professor Wang Jiguang from Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine. This trial is designed to evaluate the safety and efficacy of different doses of S086 in patients with mild to moderate primary hypertension.